A multinational study presented at the EADV Congress 2026 reveals that 39% of GLP-1 medication users reported nail detachment compared to 9% of non-users, alongside a 50% hair loss rate. Lead researchers Dr. Charles Taïeb and Dr. Bruno Halioua note that weight loss alone does not account for these symptoms, pointing to underlying scalp inflammation. Medical experts advise patients noticing benign nail or hair changes to consult their doctor rather than halt GLP-1 treatment.
EADV study findings on nail disorders
- ▪Overall, 66% of GLP-1 users in the EADV Congress 2026 study reported experiencing at least one nail disorder compared with 53% of non-users.
- ▪A multinational study presented at the EADV Congress 2026 found that 39% of GLP-1 users reported nail detachment compared to 9% of non-user controls.
- ▪In the EADV Congress 2026 study of 575 GLP-1 users and 1,329 controls, nail discoloration affected 46% of GLP-1 users compared to 17% of non-users.
EADV study findings on hair loss
- ▪A companion study presented at the EADV Congress 2026 found that 50% of GLP-1 users reported unusual hair loss compared with 34% of non-users.
- ▪Dr. Bruno Halioua reported that hair loss among GLP-1 users was typically accompanied by scalp redness, itching, or scaling, indicating an inflammatory component.
- ▪Reduced hair volume or density affected 42% of GLP-1 users compared with 19% of non-users in the EADV Congress 2026 hair study.
Analysis of GLP-1 nail study results
- ▪After adjusting for pre-existing dermatological conditions and nutritional deficiencies, nail detachment and discoloration remained two to three times more frequent in GLP-1 users.
- ▪Researchers found that weight loss alone did not explain nail differences, as GLP-1 users reported significantly more nail issues even when controlling for weight loss.
- ▪Dr. Charles Taïeb noted that while the study demonstrates a clear association between GLP-1 therapies and nail changes, it does not prove direct causation.
Expert advice on GLP-1 symptoms
- ▪Dr. Bruno Halioua emphasized that GLP-1-related hair and nail changes are usually benign and patients should consult a physician rather than discontinue their medication.
- ▪Dr. Bruno Halioua noted that scalp inflammation among GLP-1 users is treatable, though clinicians do not currently evaluate patients for the condition.
GLP-1 side effects and risks
- ▪A study led by Savanna Vidal analyzing health data from 67 U.S. healthcare organizations associated GLP-1 medication use with an increased risk of hair loss.
- ▪Common side effects of GLP-1 drugs include gastrointestinal issues such as nausea, vomiting, diarrhea, and constipation, along with potential risks of pancreatitis and gallstone disease.
GLP-1 use among children
- ▪The World Health Organization issued guidelines on October 7, 2026 advising against prescribing obesity medications to children under age 10 due to insufficient evidence on developmental safety.
- ▪GLP-1 prescriptions for U.S. children aged eight to 11 with obesity experienced a 310-fold increase between 2019 and 2026.
Lawsuits Over GLP-1 vision loss
- ▪Drugmakers Novo Nordisk and Eli Lilly dispute lawsuit claims alleging that their GLP-1 medications cause eye nerve damage leading to sudden vision loss.
- ▪Dozens of patients have filed lawsuits against drugmakers Novo Nordisk and Eli Lilly over allegations that GLP-1 medications caused sudden vision loss from eye nerve damage.
Debatable claims
- ▪GLP-1 drugs directly cause hair and nail disorders independently of weight loss
- ▪Prescribing GLP-1 obesity medications to children under ten is unjustified given current safety evidence
- ▪Patients should continue GLP-1 therapy despite experiencing cosmetic hair or nail side effects
Story comments
Loading comments…